SIGA Technologies Inc
SIGA Technologies is a U.S.-based pharmaceutical company focused on developing and commercializing treatments for orthopoxvirus infections, centered on its oral antiviral product TPOXX® (tecovirimat). The company’s business combines drug development, regulatory maintenance, intellectual property management, and third-party manufacturing and distribution arrangements across the United States and international markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCommercial sales and supply of oral TPOXX® for orthopoxvirus-related indications and government stockpiles.
Contract-related supportive services tied to product delivery, performance obligations, and customer programs.
Sales and commercialization activity outside the United States through international contract structures.
Products
Reported · share of revenue- Product Sales and Supportive Services93.1 %
- Research and Development6.9 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
SIGA sells primarily to government customers and public-health procurement channels that buy TPOXX® for biodefense preparedness and outbreak response. It also serves international counterparties and, through promotion agreements, reaches non-U.S. markets where regulatory approvals and procurement pathways differ by country.
Buys oral TPOXX® under government supply contracts for preparedness and response use.
Purchases oral TPOXX® for national stockpiles or outbreak response through country-specific arrangements.
Commercial partners that market or facilitate sales outside the U.S. under defined territory agreements.
Strategy
SIGA’s strategy centers on maintaining and extending the commercial and regulatory position of TPOXX® while preserving intellectual property protection across major markets. The company also depends on third-party manufacturing and international promotion structures, so execution quality in supply, regulatory compliance, and contract performance is central to its business model.
Patent and trademark protection supports exclusivity and commercial durability.
Market access depends on maintaining approvals and meeting local requirements.
The company depends on CMOs for production, packaging and testing.
Geography
Q2/2026SIGA is headquartered in the United States, where it retains sales and marketing rights for oral TPOXX® and manages core regulatory responsibilities. Outside the U.S., the company relies on international promotion and supply arrangements, with sales activity spanning multiple foreign jurisdictions and one-country deliveries in reported periods.
Share of the revenue the company reports by geography.
Risks
SIGA’s business is concentrated in a single product and depends on government procurement, regulatory approvals, and third-party manufacturing execution. Key risks include supply-chain disruption, cyber incidents, patent or approval setbacks, and the possibility that international biodefense demand develops more slowly than expected.
- Dependence on U.S. government contractsImpact: HighLikelihood: High
A large share of demand is tied to BARDA and other public-sector procurement.
Exposure: Revenue timing and contract continuity
- Third-party manufacturing and supply-chain disruptionImpact: HighLikelihood: Medium
SIGA does not own manufacturing infrastructure and relies on CMOs.
Exposure - Patent and trademark protection challengesImpact: HighLikelihood: Low
Exclusivity depends on maintaining broad IP coverage across jurisdictions.
Exposure: Competitive position and product lifecycle
- Regulatory approval risk outside the United StatesImpact: MediumLikelihood: Medium
Foreign commercialization requires country-specific approvals and compliance.
Exposure: International market access
- Cybersecurity and data integrity incidentsImpact: MediumLikelihood: Medium
A breach could affect clinical, manufacturing or quality records.
Exposure
Accounting
Judgemental itemsManagement identifies this as the most critical accounting estimate.
Impact: Affects timing of revenue, cost of sales and supportive services
Changes in estimates are recognized quarterly as facts become known.
Impact: Can create volatility in reported quarterly revenue and margins
Revenue depends on delivery timing and contract counterparty structure.
Impact: Can shift revenue between quarters and between U.S. and foreign markets
Similar listed companies
Publicly listed companies with a comparable business focus.
Teva Pharmaceutical Industries Limited
TEVA · Pharmaceutical Preparations
Vir Biotechnology, Inc.
VIR · Biological Products, (No Diagnostic Substances)
OraSure Technologies, Inc
OSUR · Surgical & Medical Instruments & Apparatus
OraSure Technologies is a U.S.-based diagnostics and specimen-collection company that develops, manufactures, markets, and sells rapid tests and related collection devices.
Silexion Therapeutics Corp
SLXN · Biological Products, (No Diagnostic Substances)
Silexion Therapeutics Corp is a U.S.-listed holding company whose operations are conducted primarily through its subsidiary Silexion, a clinical-stage…
Zicix Corp
ZICX · Services-Advertising
Zicix Corp is a U.S.-based services and trading company organized around product sales and cloud services.
Sangamo Therapeutics, Inc
SGMOQ · Biological Products, (No Diagnostic Substances)
Sangamo Therapeutics is a U.S.-based genomic medicine company focused on developing therapies and enabling technologies built around zinc finger biology,…
Last updated: 24/09/2026